Although this study is a single-arm study, several clinical trials test the efficacy of PD-1/PD-L1 inhibitor alone as second-line therapy in advanced NSCLC with generally consistent results, which can serve as reliable historical control [1–3, 47]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.